baber/WOPTO huggingface dataset:
Patent NZ-554682-A (NZ)
Title: Gas barrier film comprising starch, a water soluble polymer, a plasticizer, a fatty acid and an emulsifier
Inventor: HENDERSON-RUTGERS RULANDE
IPC: B32B9/02
Filed: 2005-10-18
Abstract: Disclosed is a polymer composition comprising on a dry basis: a) from 45 to 90% by weight of a modified starch or a starch and a modified starch wherein the modified starch is selected from starches modified by reaction with a hydroxyl alkyl group, an acetate or a dicarboxylic acid anhydride or a grafting polymer; b) from 4 to 12% by weight of a water soluble polymer selected from polyvinyl alcohol, polyvinylacetate, and copolymers of ethylene and vinylalcohol which have a melting point compatible with the molten state of the starch components; c) from 5 to 45% by weight of a non-crystallising mixture of sorbitol and at least one other plasticiser selected from glycerol, maltitol, xylitol, mannitol, glycerol trioleate, epoxidised linseed or soybean oil, tributyl citrate, acetyl tri-ethyl citrate, glyceryl triacetate, 2,2,4-trimethyl-1,3-pentanediol diisobutyrate; polyethylene oxide or polyethylene glycol; d) from 0.3 to 2.5% by weight of a fatty acid or salt; e) from 0.25% to 3% of an emulsifier system having a hydrophilic lipophilic balance value between 2 and 10, and wherein the polymer composition is in the form of a gas barrier film. Also disclosed is a co-extruded laminate which comprises polyethylene, polypropylene or polylactic acid and the above composition for thin film packaging applications.
Patent NZ-556095-A (NZ)
Title: Fixed dosing of her antibodies
Inventor: ALLISON DAVID E
IPC: C07K16/32
Filed: 2005-06-15
Abstract: Provided is a use of at least one fixed dose of pertuzumab in the preparation of a medicament for the treatment of cancer in a human patient, wherein the fixed dose is selected from the group consisting of approximately 420mg, approximately 525mg, approximately 840mg, and approximately 1050mg of pertuzumab. Further provided are corresponding pharmaceutical formulations and kits.
Patent NZ-560346-A (NZ)
Title: Dynamically configurable relay element and related methods
Inventor: GUZMAN-CASILLAS ARMANDO
IPC: H01H47/00
Filed: 2006-06-23
Abstract: Disclosed is a dynamically configurable relay element, which is configured to protect an electrical system. The relay element comprises of: a calculated relay operating quantity; a calculated relay pickup setting; a calculated time dial; a calculated operating time; and a plurality of dynamically calculated variables that define a characteristic of the dynamically configurable relay element.
Patent NZ-562531-A (NZ)
Title: Combustion gas cartridge for gas fastening device with improved exhaustion through multiple zones
Inventor: MARION CYCRIL
IPC: F17C1/00
Filed: 2006-04-21
Abstract: Disclosed is a combustion gas cartridge for a gas internal combustion fastening device. The device comprises of an external casing (2) over which is crimped the edge (6) of an internal cup (5) beyond which an outlet end (8) projects. The external casing of the cartridge is stepped and includes at least three longitudinal zones having different respective diameters. The zones comprise: a first edge zone (9); a second bearing zone (10) for the head of a crimping machine having a smaller diameter than that of the edge zone; and a third zone (11) having a diameter equal to or greater than that of the edge zone and forming an annular shoulder (12) together with the second bearing zone for the crimping head.
Patent NZ-565522-A (NZ)
Title: Use of 3,11b-cis-dihydrotetrabenazine for the treatment of symptoms of Huntington's disease
Inventor: TRIDGETT ROBERT
IPC: A61K31/473
Filed: 2006-07-13
Abstract: Disclosed is the use of 3,11 b-cis-dihydrotetrabenazine or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for use in halting or slowing the progress of one or more symptoms of Huntington's disease in a patient, wherein the symptoms are selected from involuntary movements and degeneration in gait, or in the prophylactic treatment of a patient identified as carrying the mutant gene responsible for Huntington's disease, or in the prophylactic treatment of a patient within the age range 15 - 50 years who is carrying the mutant form of the HD gene but who have not yet developed symptoms of the disease, the prophylactic treatment being for the purpose of preventing or slowing the onset of symptoms associated with Huntington's disease.
Patent NZ-567317-A (NZ)
Title: Accident prevention insole of multi-layer fabric with a resin layer applied to each non-aramidic fabric layer.
Inventor: FENZI ROBERTO
IPC: A43B13/12
Filed: 2006-09-26
Abstract: An accident prevention insole for a safety shoe includes a base surface and a top surface opposite to the base surface. The accident prevention insole (1) consists of a multilayer fabric (4) which can be crossed-through by needles with a diameter lower than 14 tenths of millimetres perpendicularly driven to the insole with a load of at least 90 N. The insole can then be directly sewn to an upper of an accident prevention footwear. Each layer (5) of the multi-layer fabric includes a fabric layer (6) and at least a resin surface layer (7) applied to the fabric layer. The fabric layers consist of non-aramidic fibres woven in a double face weave to increase the weft density.
Patent NZ-569979-A (NZ)
Title: Rapid saccharide biomarker assay
Inventor: AXFORD JOHN
IPC: G01N33/00
Filed: 2006-06-09
Abstract: Provided is a diagnostic method comprising comparing a biosugar profile of a previously obtained biological sample of a patient suspected of having a rheumatic disease to a healthy biosugar profile from the same type of biological sample, wherein the biosugar profile is characterized in that it is the biosugar profile of one or more proteins, peptides, lipids, or polysaccharides and a deficiency in two or more essential saccharides can be selected from the group consisting of G1(alpha1,6)-bis, G2bis, G1(alpha1,6)-bisF, a1G2, a1G1bis, a1G2 + F2 and a1G1 + F2.
Patent NZ-573835-A (NZ)
Title: Apparatus and method for manipulating images
Inventor: ELGAR ADAM
IPC: G06Q40/02
Filed: 2004-02-17
Abstract: A computer system for applying a personalized image to a financial account access means corresponding to a financial account of a customer is provided. The computer system includes: a financial account association table associating financial data, corresponding to the financial account of the customer, with a customer identifier; an image manipulation emulator for associating the customer identifier with user image selection data based on user selections made on a user interface in relation to a graphical representation of at least a portion of an original image held in an image store; and an image application means for applying the personalized image to the financial account access means, the personalized image being based on the user image selection data associated with the customer identifier by the image manipulation emulator. The system maintains at least the financial account association table securely from the user interface. (62) Divided Out of 543516
Patent NZ-573911-A (NZ)
Title: Process for the preparation of (1r,2r)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol
Inventor: HELL WOLFGANG
IPC: C07B57/00
Filed: 2007-07-23
Abstract: Disclosed is a process for preparing (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol, or an acid addition salt thereof, comprising the step of (a) reacting a compound of general formula (I), wherein R represents -C1-6-alkyl, -C3-8-cycloalkyl, -C1-3-alkylene-phenyl, -C1-3-alkylene-naphthyl, tetrahydropyranyl or -C(=O)-C1-6-alkyl, with ethyl magnesium halide in an inert reaction medium under Grignard conditions; (b) transferring the thus obtained compound of general formula (II), to a compound of general formula (III), optionally in form of an acid addition salt; (c) deprotecting the thus obtained compound of general formula (III) to obtain (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol of formula (IV); (d) optionally converting the thus obtained (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol into an acid addition salt.
Patent NZ-575472-A (NZ)
Title: Cylindrical liquid applicator with cover
Inventor: SLADE ROBERT CALVIN
IPC: B05C7/08
Filed: 2009-03-12
Abstract: A plumber's liquid applicator for applying liquid to join pipes or fittings, the applicator including an elongate body including a handle 1 and a stem 2 extending from the handle 1, an absorber 5 for mounting to the stem 2 and for insertion into the liquid so as to absorb the liquid to be applied to the pipes or fittings, and a seal 3 for mounting to the body and able to be pushed into engagement within an opening of a container 6 so that the absorber 5 is sealed within the container 6.
Patent NZ-577109-A (NZ)
Title: Benzamide derivatives as ep4 receptor agonists
Inventor: GAIBA ALESSANDRA
IPC: A61P19/00
Filed: 2007-12-12
Abstract: Disclosed is a compound of formula (I), wherein the substituents are as defined in the specification. The compounds are benzamide derivatives as EP4 receptor agonists useful in the treatment of pain.
Patent NZ-585207-A (NZ)
Title: Protease detection using a polypeptide comprising a chromogenic amino acid
Inventor: SCHOUTEN JAMES ALEXANDER
IPC: B01L3/00
Filed: 2008-11-13
Abstract: Disclosed is a method of detection of a protease enzyme in a sample, comprising the steps of: (i) exposing the sample to a polypeptide comprising a chromogenic amino acid, wherein the chromogenic amino acid is flanked by at least one amino acid to the N and C termini thereof, the amine group of the chromogenic amino acid has a pKa of less than 5 and the chromogenic amino acid is capable of reacting with a conjugated aldehyde, and wherein the polypeptide comprises a target sequence for a target protease which is capable of cleaving the peptide bond comprising the amino group of the chromogenic amino acid; and allowing the protease to cleave the polypeptide and create a fragment displaying the chromogenic amino acid to the N-terminus of the fragment; (ii) reacting a conjugated aldehyde with the fragment comprising the chromogenic amino acid to produce a coloured adduct; and (iii) detecting the coloured adduct, the presence of the coloured adduct being indicative of the presence of the protease enzyme in the sample. Further disclosed is a product for detecting a protease enzyme in a sample comprising: (i) a polypeptide comprising a chromogenic amino acid, wherein the chromogenic amino acid is flanked by at least one amino acid to the N and C termini thereof, the amine group of the chromogenic amino acid has a pKa of less than 5 and the chromogenic amino acid is capable of reacting with a conjugated aldehyde, and wherein the polypeptide comprises a target sequence for a target protease which is capable of cleaving the peptide bond comprising the amino group of the chromogenic amino acid; and (ii) a solid support, on which the polypeptide is immobilisable to permit the sample to be exposed to the polypeptide and, if the protease is present in the sample, to cleave the polypeptide and create a fragment displaying the chromogenic amino acid to the N-terminus of the fragment; and (iii) a conjugated aldehyde which reacts with the fragment comprising the chromogenic amino acid to produce a coloured adduct.
Patent NZ-587829-A (NZ)
Title: Crystalline forms and two solvated forms of 4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]quinolin-2(1h)-one lactic acid salts
Inventor: GIRON DANIELLE
IPC: A61P35/00
Filed: 2009-03-18
Abstract: Disclosed is a substantially pure crystalline anhydrous form II of 4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one lactic acid salt characterized by an x-ray powder diffraction pattern that shows maxima at 8.2, 11.8, 12.9, 13,8, 14.7, 16.6, 18.5, 20.3, 23.5 degrees, 2 theta. The crystalline form is useful for treating a disease which responds to an inhibition of VEGFR2 and FGFR3 activity, such as prostate cancer, colorectal cancer, breast cancer, multiple myeloma, pancreatic cancer, small cell carcinoma, acute myelogenous leukemia, chronic myelogenous leukemia, myeloproliferative disease, non-small cell leukemia, small cell leukemia, chronic lymphoid leukemia, sarcoma, melanoma, lymphoma, thyroid cancer, neuroendocrine cancer, renal cell cancer, gastric cancer, gastrointestinal stromal cancer, glioma, brain cancer, bladder cancer and cholangiocarcinoma.
Patent NZ-588037-A (NZ)
Title: Serotonin transporter gene SLC6A4 and treatment of alcoholism
Inventor: JOHNSON BANKOLE A
IPC: G01N33/48
Filed: 2009-02-27
Abstract: Disclosed is a method of predicting a predisposition to developing an addictive disease or disorder in a test subject, said method comprising: providing a biological sample obtained from the test subject; determining whether the subject has the G allele or is homozygous for the T allele of the single nucleotide polymorphism rsl042173 of the serotonin transporter gene SLC6A4, wherein the presence of the G allele is an indication that the test subject has a lower predisposition to developing an addictive disease or disorder relative to a subject homozygous for the T allele and wherein homozygosity of the T allele in the test subject is an indication that the test subject has a higher predisposition to developing an addictive disease or disorder compared with a subject with the G allele; thereby predicting a predisposition to developing an addictive disease or disorder in a subject. Further disclosed is the use of an antagonist of the serotonin receptor 5-HT3 in the manufacture of a medicament for treating a subject with an addictive disease or disorder, wherein: (a) the use includes determining whether the serotonin transporter gene SLC6A4 of the subject has the LL genotype of functional polymorphism serotonin transporter-linked polymorphic region 5-HTTLPR, and determining whether the subject has the G allele or is homozygous for the T allele of the single nucleotide polymorphism rsl042173 of the serotonin transporter gene SLC6A4; and, (b) the antagonist of the serotonin receptor 5-HT3 is formulated for administration to a patient found to have the LL and TT genotypes so as to treat an addictive disease or disorder.
Patent NZ-589272-A (NZ)
Title: Protective work wear
Inventor: DANCEY LEE SIMON
IPC: A41D13/06
Filed: 2009-04-16
Abstract: Protective work wear comprises a fabric portion extending to a flexible joint region of a user, a protective portion 12 hinged to the fabric portion and movable from a protective position located over the joint region to a stowed position away from the joint region, and respective securing means adapted to selectively secure the protective portion 12 in the protective and stowed positions.
Patent NZ-593909-A (NZ)
Title: Cord hanger of slotted sheet material
Inventor: CLARK STEVEN RUPERT
IPC: F16G11/00
Filed: 2011-12-13
Abstract: A lead hanger for mounting onto pipes, the body of the lead hanger being formed from sheet material. An internal pipe aperture and at least two internal lead apertures extend through the sheet. The internal pipe aperture communicates with the bottom edge of the sheet via a pipe slot. The internal lead apertures are situated adjacent respective opposite side edges of the sheet and communicate with respective adjacent side edges of the sheet via lead slots. The hanger can be fitted over a pipe by sliding the pipe through the pipe slot, and a lead can be supported in the internal lead aperture.
Patent NZ-597226-A (NZ)
Title: Heterocyclic sulfonamides, uses and pharmaceutical compositions thereof
Inventor: FLIRI ANTON FRANZ JOSEPH
IPC: A01N29/06
Filed: 2010-06-22
Abstract: Patent No. 597226 Disclosed is a compound of formula I, such as N-{ (3S,4S)-4-[4-(5-cyano-2-thienyl)phenoxy]tetrahydrofuran-3-yl} propane-2-sulfonamide, which is useful for treating acute neurological and psychiatric disorders.
Patent NZ-599917-A (NZ)
Title: Methods and apparatus for adaptable pressure treatment of sleep disordered breathing
Inventor: MARTIN DION CHARLES CHEWE
IPC: A62B7/04
Filed: 2010-11-16
Abstract: Disclosed is a method of controlling a respiratory pressure treatment device. The method includes generating a flow of breathable gas at a patient interface, the flow of breathable gas being synchronized with a respiratory cycle. The flow of breathable gas includes inspiratory pressure portions (ins) and expiratory pressure (exp) portions such that an expiratory pressure portion (exp) is at a pressure lower than an inspiratory pressure portion (ins). A flow of breathable gas to the patient interface is measured and the measurement is analysed to detect an occurrence of a sleep disordered breathing (SDB) event. Control parameters of an expiratory pressure portion (exp) are modified in response to the detection of the occurrence of the SDB event, to modify a reduction in expiratory pressure delivered during the expiratory pressure portion (exp). The SDB event consists a persistent obstruction to flow.
Patent NZ-600866-A (NZ)
Title: Alcohol production process
Inventor: BARKER WILL DAVID
IPC: C12P1/04
Filed: 2011-01-14
Abstract: Patent No. 600866 Disclosed is a method for improving carbon capture by microbial fermentation of a gaseous substrate comprising CO, the method comprising contacting the gaseous substrate with a fermentation broth comprising one or more microorganisms in a bioreactor operated at fermentation reaction conditions, and applying an electrical potential across the fermentation broth.
Patent NZ-618550-A (NZ)
Title: Device for unwinding and winding up one or more lines
Inventor: WIDEGREN MICHAEL
IPC: H02G11/02
Filed: 2012-06-18
Abstract: Dislosed is a device (1) for unwinding and winding up one or more lines (2) for the interruption-free connection of each of the one or more lines between two connecting points, wherein the interruption-free connection can be produced between a fixed first connecting point (7) and a second connecting point which is at a variable spacing or in each case one of a plurality of second connecting points which are at different spacings. The device comprises a rotatable winding body (3) for unwinding and winding up the one or more lines, and the line/lines is/are routed from the first fixed connecting point in a first part section from a stationary, first position (41) which is coaxial with respect to the winding body to a second position (42) which lies opposite the first position, and from said second position to a third position (43) which is substantially in one plane with the first position but can be rotated with the winding body; here, the line/lines is/are routed in the first part section in a helical shape at least in sections. The line/lines is/are subsequently routed from the third position in a second part section to the circumferential side of the winding body and optionally via a number of windings around the winding body to the second connecting point. The second position is arranged to be freely rotatable independently of the winding body.
Patent NZ-620946-A (NZ)
Title: Enhancement of beer flavor by a combination of pichia yeast and different hop varieties
Inventor: SARENS SOFIE
IPC: C12R1/84
Filed: 2012-09-03
Abstract: The disclosure relates to a method of brewing beer comprising providing a wort; adding at least one hop variety to obtain a hopped wort; fermenting the hopped wort with a Pichia spp. yeast strain, and then fermenting the hopped wort with a yeast strain belongs to the genera Saccharomyces or Brettanomyces to obtain a beer. The hop variety may be Saaz, Nelson Sauvin, Cascade or Amarillo. The yeasts may be Pichia kluyveri, Saccharomyces cerevisiae, Saccharomyces pastorianus or Brettanomyces bruxellensis. The yeast may be used to increase the levels of isoamyl acetate, isobutyl acetate, ethyl propionate, ethyl valerate, ethyl butyrate, ethyl decanoate and ethyl octanoate in the beer.
Patent NZ-627539-A (NZ)
Title: A blank for forming a container
Inventor: JOHNSON GREGORY
IPC: B65D5/42
Filed: 2013-03-05
Abstract: A blank for forming a container including a series of five panels each with opposing flaps is described. The configuration seeks to minimise the amount of time spent applying fastenings, e.g. glue, during the construction of the box as well as reducing the volume of fastening(s) required. When folded, the flaps and the sides create a base and walls, forming an approximately rectangular box suitable for encasing six-packs of beverages or other objects. The side walls are inclined at deformation sections (508) and the blank is enclosed at an overlapping section (18).
Patent NZ-629913-A (NZ)
Title: Anti-ox40 antibodies and methods of using the same
Inventor: LIU YONG-JUN
IPC: C12N15/13
Filed: 2011-08-23
Abstract: Disclosed is an antibody which binds to OX40, where the CDR regions are CDR H1 - SHDMS CDR H2 - AINSDGGSTYYPDTMER CDR H3 - HYDDYYAWFAY CDR L1 - RASKSVSTSGYSYMH CDR L2 - LASNLES CDR L3 - QHSRELPLT
Patent NZ-705096-A (NZ)
Title: Perforin inhibiting benzenesulfonamide compounds, preparation and uses thereof
Inventor: SPICER JULIE ANN
IPC: C07D417/14
Filed: 2013-08-21
Abstract: The present invention relates to compounds capable of modulating perforin activity, to their preparation, and to their use as tools for biological studies or as agents or drugs for immunosuppressive therapies. More specifically, the present invention relates to benzenesulfonamides and related compounds of formula (Ia) wherein Ring A is selected from optionally substituted phenylene, pyridinylene or thiophenylene; Ring B is selected from optionally substituted phenylene or pyridinylene; Ring C is selected from thiophenylene, pyridinylene or thiazolylene; Ring D is a benzofused 9 11 membered heterocyclyl or benzofused 9 11 membered heteroaryl; L is a linker selected from branched and unbranched C1-C4 alkylene, -S(O)2-NH-, C(O) NH-, -NH-C(O)-NH-, -S(O)2-NH-C(O)-NH-, -S(O)2-NH-C(O)– and -CH=CH-; wherein Rings B and C, and Rings C and D, are connected to each other via a C-C bond at any of the available C atoms on each respective ring and pharmaceutically acceptable salts, solvates, and hydrates thereof.
Patent NZ-712660-A (NZ)
Title: Dicarboxylic acid compound
Inventor: UTO YOSHIKAZU
IPC: C07D401/14
Filed: 2014-04-23
Abstract: The problem is to provide a pharmaceutical for the prevention or treatment of hyperphosphatemia. Solution: A compound having general formula (I) or a pharmaceutically acceptable salt thereof. (In the formula, R1 = alkyl, alkoxyalkyl, cycloalkyl or the like, R2 = hydrogen or halogen, R3 = hydrogen, halogen, halogenoalkyl, halogenoalkoxy, cycloamino, dialkylamino, cycloalkylalkoxy or alkoxy, A = cycloalkyl, X = CH or N, Y = CH or N, Z = CH or N, n = 1-4.)
Patent NZ-721009-A (NZ)
Title: A checkpoint inhibitor and a whole cell mycobacterium for use in cancer therapy
Inventor: AKLE CHARLES
IPC: A61K39/395
Filed: 2014-12-16
Abstract: An immunomodulator for use in the treatment, reduction, inhibition or control of a neoplastic disease in a patient intended to undergo checkpoint inhibition therapy, simultaneously, separately or sequentially with administration of the immunomodulator. The immunomodulator preferably comprises a whole cell Mycobacterium, for example, M. vaccae or M. obuense. In a specific embodiment the invention is the use of a non-pathogenic heat-killed whole cell Mycobacterium in the manufacture of a medicament for the treatment, reduction, inhibition or control of a neoplastic disease in combination with a checkpoint inhibitor, wherein the non-pathogenic heat-killed whole cell Mycobacterium is M. obuense, wherein said checkpoint inhibitor is a cell, protein, peptide, antibody or antigen binding fragment thereof that binds CTLA-4, PD-1, PD-L1 and combinations thereof, and wherein the non-pathogenic heat-killed whole cell Mycobacterium is to be intradermally administered in one or more doses prior to administration of a checkpoint inhibitor.